{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sundaresh SN"],"funding":["Paul G. Allen Frontiers Group","U.S. Department of Defense"],"pagination":["e70947"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12701366"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(12)"],"pubmed_abstract":["<h4>Introduction</h4>Oligomeric species of tau are a hallmark of Alzheimer's disease (AD). Given the evidence implicating protein phosphatase 2A (PP2A) in the molecular pathogenesis of tauopathies, we sought to determine whether manipulating the expression of enzymes that regulate PP2A activity, such as leucine carboxyl methyltransferase 1 (LCMT-1) and protein methylesterase 1 (PME-1), would alter pathological responses to oligomeric tau.<h4>Methods</h4>We tested the effect of LCMT-1 and PME-1 overexpression on cognitive and electrophysiological impairments caused by exposure to either recombinant oligomeric human tau or oligomeric tau prepared from mice subjected to blast-induced traumatic brain injury.<h4>Results</h4>We found that LCMT-1 overexpression reduced sensitivity while PME-1 ove"],"journal":["Alzheimer's & dementia : the journal of the Alzheimer's Association"],"pubmed_title":["PP2A methylesterase, PME-1, and PP2A methyltransferase, LCMT-1, control sensitivity to impairments caused by injury-related oligomeric tau."],"pmcid":["PMC12701366"],"funding_grant_id":["W81XWH‐15‐1‐0550","HT9425‐23‐1‐0384","W81XWH-15-1-0550","HT9425-23-1-0384","W81XWH-12-1-0579","12347","W81XWH‐12‐1‐0579"],"pubmed_authors":["Liang S","Vogel EW","Shen L","Asam K","Gnanaprakash M","Arancio O","Zhang H","Morrison B","Fa M","Staniszewski A","Masone A","Nicholls RE","Berman HL","Kanaan NM","Sundaresh SN","Hue CD","Gill Z","Acquarone E"],"additional_accession":[]},"is_claimable":false,"name":"PP2A methylesterase, PME-1, and PP2A methyltransferase, LCMT-1, control sensitivity to impairments caused by injury-related oligomeric tau.","description":"<h4>Introduction</h4>Oligomeric species of tau are a hallmark of Alzheimer's disease (AD). Given the evidence implicating protein phosphatase 2A (PP2A) in the molecular pathogenesis of tauopathies, we sought to determine whether manipulating the expression of enzymes that regulate PP2A activity, such as leucine carboxyl methyltransferase 1 (LCMT-1) and protein methylesterase 1 (PME-1), would alter pathological responses to oligomeric tau.<h4>Methods</h4>We tested the effect of LCMT-1 and PME-1 overexpression on cognitive and electrophysiological impairments caused by exposure to either recombinant oligomeric human tau or oligomeric tau prepared from mice subjected to blast-induced traumatic brain injury.<h4>Results</h4>We found that LCMT-1 overexpression reduced sensitivity while PME-1 ove","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-15T06:09:41.97Z","creation":"2026-06-30T03:22:24.903Z"},"accession":"S-EPMC12701366","cross_references":{"pubmed":["41388803"],"doi":["10.1002/alz.70947"]}}